Yeah, right. And this is a, you know, a meeting where the very biggest companies are completely dwarfed by the size of a trillion dollar company like Invidious striding into the room.

It associates biotech with one of the biggest

buzzwords of the last year which is AI and that's that's exactly what he was

there for.

I'm Mary Long and that's Carl Teal, a Motley Fool biotech analyst.

Dieter Woolard caught up with Carl to get some takeaways from the recent

JPMorgan Healthcare Conference where health care and biotech companies get some takeaways from the recent JPMorgan Health Care Conference,

where health care and biotech companies

tell investors what they're up to.

Dider and Carl discuss how Vertex Pharmaceuticals

could change pain medication,

why winners will probably keep on winning in the weight loss drug

space, and a cancer treatment that's frustrating investors.

Something that's to happen last year, the big story of, you know,

G.P. 1 drugs and diabetes care kind of reinvigorated, it seemed to me,

the whole space in general. I mean, that's probably overstating things,

but you saw these companies like Eli Lilly

and Nova Nordics, they had this monster year.

They couldn't get these drugs out fast stuff.

Every time I turn on the TV TV somebody is offering a new service

trying to get these drugs out so this seems like an overnight success but this is

like a two-decade story what what is happening in this space?

...